

Karen Chen, PA-S

Faculty advisor: Amanda Murphy, PA-C

Department of Medical Science

## ABSTRACT

As the number of uncontrolled eczema cases continues to rise, providers are forced to re-evaluate the efficacy of these traditional topicals and look to other drug classes for relief. This presentation reviews the risks and benefits of the first FDA-approved injectable biologic for eczema called Dupixent®. So far, the response has been promising. Based on the evidence presented, it's safe to presume patients with moderate-to-severe eczema can be reassured of a more optimistic prognosis.

## INTRODUCTION: ATOPIC DERMATITIS

- Atopic dermatitis (AD) is the most common type of eczema, known for the inflamed and leathery skin found in flexural creases.
- Its pathogenesis is multifactorial- made up of both genetics and environmental factors.
- Half of all adults with moderate to severe AD report that this disease negatively impacts their life.
- Many topical medications are inadequate at preventing recurring flare-ups and controlling itch, especially those with severe disease.

## TOPICAL TREATMENTS

- Therapy is **PALLIATIVE** and depends on severity, frequency, and site.
- Main categories of treatment
  - Topicals (steroids, calcineurin inhibitors)
  - Immunosuppression (methotrexate, oral steroids)
  - Phototherapy
- Intense moisturization + avoid irritants!
- GOAL: reduce flare-ups + reduce itch & inflammation

## DUPIXENT (Dupilumab)

Regeneron Pharmaceuticals, Inc and Sanofi.

In 2017, Dupixent became the **first FDA-approved** monoclonal antibody for severe AD refractory to prescription topicals in patients 6 years and up.

Any other indications other than eczema?

- Asthma
- Chronic sinusitis with nasal polyposis
- Research on its efficacy against eosinophilic esophagitis is still pending, but results are hopeful

Quick overview of Dupixent

- **Drug class:** biologic (monoclonal antibody)
- **Dosing:** every other week at 300 mg via a patient-administered subcutaneous injection
- **Pharmacodynamics:** blocks messengers that induce the inflammatory skin symptoms characteristic of eczema
- Most common **side effects:** conjunctivitis, cold sores, injection site reaction

GOAL: reduce eczematous flare-ups, itch, inflammation

## CONCLUSION

Dupixent®'s success offers a more optimistic prognosis for moderate-to-severe AD patients. **This is the only systemic medication that has been proven to significantly relieve AD symptoms** without the effects of long-term steroids or immunosuppression.

### Patient testimonies:

“I was in bad shape before starting DUPIXENT. Now, I feel like I have control over my disease.” -Rachel

“I’ve had itchy skin since I was a baby. With DUPIXENT, I finally feel a difference.” -Chloe


“I don’t want to be defined by my atopic dermatitis. Since starting DUPIXENT, I can roll up my sleeves.” -Shawn

- References:
1. National Eczema Association. 2022. What are biologics treatments for eczema?. Available at: <https://nationaleczema.org/eczema/treatment/injectables/>. Accessed 11 January 2022.
  2. Real Patient Stories. Discover DUPIXENT® (dupilumab) Resources. <https://www.dupixenthcp.com/atopicdermatitis/support-resources/resource-library>. Published November 2021. Accessed January 11, 2022.
  3. Remitz A, Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf. 2009;8(4):501-506. doi:10.1517/14740330902969441
  4. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218-1233. doi:10.1016/j.jaad.2014.08.038
  5. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347.
  6. Simpson EL. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2017;7(2):243-248. doi:10.1007/s13555-017-0181-6

18+ YEARS

Itch reduction sustained at 1 year (secondary endpoint)<sup>1,3,a-c</sup>

### CHRONOS: Concomitant Therapy With TCS



Adolescent patient achieved a 2-point improvement in IGA

